New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
November 21, 2019. Effect of acalabrutinib in combination with bendamustine plus rituximab on survival endpoints in older patients with mantle cell lymphoma: insights from the ECHO trial. healthbook TIMES Onco Hema. 2024;22(4):22-29. doi:10.36000/HBT.OH.2024.22.163 ClinicalTrials.gov. Updated February 19, 2025. Accessed May 14, 2025.
Let's personalize your content